Two Onc Docs

This week's episode will be focusing on Ovarian Cancer with 2025 updates since we last covered this topic in 2022. We will go over all important details on the risk factors, presentation, diagnosis, staging & treatment options for both localized and metastatic disease. 

This week's episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others. 

This week's episode will be focusing on exciting data to come at the ASCO Annual Meeting 2025 starting with the plenary sessions, then a special focus on the GU abstracts, including prostate CA, renal cell carcinoma, bladder CA, and a quick shout-out for some of the medical education sessions.

This week's episode will be focusing on hepatocellular carcinoma (HCC). We will go over important details on assessing liver function, staging of HCC and loco-regional as well as systemic treatment options for HCC.

This week's episode will be focusing on Hematopoietic Stem Cell Transplant. We welcome our guest  Dr. Jeff Auletta, Senior Vice President, National Marrow Donor Program, and Chief Scientific Director,Center for International Blood and Marrow Transplant Research. Part 2 discusses conditioning regimens, graft-vs-host disease, toxicities, and Dr. Auletta's career path.

This week's episode will be focusing on Hematopoietic Stem Cell Transplant. We welcome our guest  Dr. Jeff Auletta, Senior Vice President, National Marrow Donor Program, and Chief Scientific Director,Center for International Blood and Marrow Transplant Research. Part 1 discusses important basics including what a transplant is, types of transplant & associated risks, types of donors, how to find a donor, and barriers/inequities of finding a donor.

This week's episode is part 2 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of non-seminoma last year, released 4/22/2024, but today, we will be repeating a quick overview of the staging and management for initial treatment of non-seminoma as well as refractory disease.

This week's episode is part 1 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of testicular CA last year, released in April 2024, but today, we will be repeating a quick overview of risk factors and staging for testicular cancer, as well as the management of seminoma.

This week's episode will be focusing on an update of CLL. We will go over  important details on the presentation, diagnosis, prognostic factors, and treatment options for initial and refractory disease, as well as key toxicities. 

We are so excited to welcome back Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at MSK in NYC, and co-host of the podcast 'The Good News About Cancer'. This episode will cover metastatic prostate cancer including board review pearls & key toxicities of treatments, upcoming exciting research in PCa, and advice for trainees/early career faculty.

We are so excited to welcome Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at Memorial Sloane Kettering in NYC. This episode will cover localized prostate cancer, risk factors, staging, role of PET PSMA, risk stratification, treatments, as well as introduce biochemical recurrence.

Today's episode is focusing on what you need to know regarding metastatic colon cancer. This will include the need to know about molecular studies, treatment, and surgery for oligometastatic disease. There has been three breakthroughs since we last covered this topic in the treatment of metastatic CRC based on molecular findings that we will go over today.

Today's episode is focusing on what you need to know regarding early stage colorectal cancer (CRC) as of 2025. The last time we covered this topic was in 2023 and things continue to change. We will go over all the important details on the diagnosis, presentation, diagnostic work-up, role of ctDNA, staging, treatment, and surveillance of localized CRC. 

We are so honored to welcome back Dr. S. Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He is also Editor-In-Chief of Blood Cancer Journal and the Chairperson of the Board of the International Myeloma Foundation. This week's episode will be focusing on additional pearls for the treatment of Multiple Myeloma including options for refractory disease, as well as advice for trainees.

Today we will be discussing a few of the exciting abstracts presented at ASCO GU (Feb 13-15 2025) for prostate CA (TALAPRO-2), bladder CA (EV-302, CM-274, NIAGARA), and RCC (COSMIC-313, KIM-1).

Today we will be discussing exciting data to come at ASCO GU (Feb 13-15 2025) in terms of research for prostate CA, bladder CA, RCC and other rarer GU tumors.

We are so honored to welcome Dr. S. Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He is also Editor-In-Chief of Blood Cancer Journal and the Chairperson of the Board of the International Myeloma Foundation. This week's episode will be focusing on Multiple Myeloma symptoms, diagnostic criteria, work-up and initial treatment.

This week's episode will be focusing on additional details for Extensive Stage Small Cell Lung Cancer (SCLC), options for relapsed/refractory disease & advice for trainees. We are so excited to welcome back Dr. Stephen Liu international expert for lung cancer, Director of Thoracic Oncology & Developmental Therapeutics at Georgetown Lombardi Cancer Center and Co-Host of the IASLC Podcast.

This week's episode will be focusing on Small Cell Lung Cancer (SCLC). We will go all the important details on risk factors, diagnostic work-up, staging and treatment of both locoregional and metastatic SCLC. We are so excited to welcome Dr. Stephen Liu international expert for lung cancer, Director of Thoracic Oncology & Developmental Therapeutics at Georgetown Lombardi Cancer Center and Co-Host of the IASLC Podcast.

This week's episode will be re-discussing one of the myeloproliferative neoplasms, Polycythemia Vera (PV). We will go over the important details on the diagnosis, risk stratification for thrombus and treatment.

Happy New Year! This week's episode will go over important details related to immune checkpoint inhibitors (ICIs) and immune-related adverse events (irAEs), with general management strategies for each of the most common iRAEs.

This week's episode will be focusing on advanced Thymoma and Thymic Carcinoma, board review pearls, and career advice for trainees & early career oncologists. We are back with Dr. Pat Loehrer, who is a legend when it comes to the treatment of Thymoma. 

This week's episode will be focusing on localized Thymoma and Thymic Carcinoma. We are so honored to have Dr. Pat Loehrer here with us today who is a legend when it comes to the treatment of Thymoma. He is a Distinguished Professor of Medicine Joseph W. and Jackie J. Cusick Professor of Oncology, Director for Center of Global Oncology and Health Equity and prior cancer center director at Indiana University.

This week's episode will be focusing on Metastatic Non-small Cell Lung Cancer (NSCLC). We are back with Dr. Jennifer Marks, Thoracic Oncologist at the Dana-Farber Cancer Institute. We will go all the important details on the quickly growing and changing systemic therapy options including traditional chemotherapy, immunotherapy and targeted agents 

This week's episode will be focusing on Localized Non-small Cell Lung Cancer (NSCLC). We are very excited to have Dr. Jennifer Marks with us today. Dr. Marks is a thoracic oncologist at the Dana-Farber Cancer Institute, Instructor in Medicine at Harvard Medical School, who also recently took her oncology boards. We will go all the important details on basic of staging, treatment for resectable and unresectable localized NSCLC, and updates in terms of peri-operative and targeted therapies

This week's episode will be focusing on Hemoglobin (Hb) electrophoresis. We will go important details on what Hb electrophoresis is, the normal breakdown of adult hemoglobin, and specific hemoglobinopathies (thalassemias, sickle cell, Lepore...) you can be tested on during your ITEs and hematology boards.

In honor of National Family Health History Month in November, we have a special guest. We share the story of an incredible colorectal cancer survivor and health advocate, Marisa Peters, who was a Broadway vocalist and a very healthy, active mom to 3 young boys, yet diagnosed with stage 3 rectal cancer at only 39 years old. 

This week's episode is part 3 of 2024 updates focusing on treatment options for metastatic breast cancer. We will cover important details on systemic therapy related to metastatic breast cancer & key toxicities. We are honored to have Dr. Eleonora Teplinsky, a board-certified medical oncologist specializing in breast and gynecologic oncology, as a guest sharing some pearls.

This week's episode  is part 2 of 2024 updates focusing on treatment options for localized breast cancer. We will discuss important details on radiation, as well as therapies based on ER/PR/her2 receptor status. We are honored to have Dr. Eleonora Teplinsky, a board-certified medical oncologist specializing in breast and gynecologic oncology, as a guest sharing some pearls.

We are continuing our 2024 updates, this week's episode will be an intro to breast cancer. Today's will include high yield tips on screening, prevention, ductal carcinoma in situ DCIS, lobular carcinoma in situ LCIS, as well as introduce invasive localized disease.

This week's episode will be discussing our favorite heme/onc board review resources.  This is pertinent to new fellows who are starting to think about how to study during fellowship, preparation for ITEs and of course studying for the boards.

We are doing a special episode this week to cover some of the key GU abstracts from ESMO 2024. We cover an update on the STAMPEDE prostate cancer trial, SUNNIFORECAST in non-clear cell renal cell carcinoma, SunRISe-4 in bladder cancer, and more.

In Part 2 we discuss how to deal with patients of different backgrounds, navigating spiritual & emotional challenges in oncology, tips for physicians who are experiencing moral distress & compassion fatigue, as well as general career advice.  We are so honored to have Dr. Janet Abrahm with us who is a national leader in the field of palliative care and a professor at Harvard Medical School.

This week's episode will be focusing on final board review tips. We will go over our highest yield cheat sheet topics, and how we prepared the days leading up to our exam. We took our boards three years ago now, but the stress leading up to the exam is certainly fresh in our minds.

In Part 1 we discuss how to explain palliative care to patients, pain and anti-emetic management, non-pharmacologic strategies, and current innovations within palliative care.  We are so honored to have Dr. Janet Abrahm here with us who is a national leader in the field of palliative care and a professor at Harvard Medical School.

This week's episode will be repeating our episode on hemophilias with some updates. We will go over all high yield facts regarding both hemophilia A and B  for your boards and end with a little bit about acquired hemophilias. 

This week's episode will be discussing updates from ASCO 2024 next with the practice changing NADINA trial presented on the Sunday of ASCO by Dr. Christian Blank during the plenary sessions:  A multicenter, randomized, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. We discuss the staging and prior standard of treatment for locally advanced melanoma, key findings from NADINA, and how these data may impact clinical practice.

Today's episode is a continuation on fast facts for the IM Board review focusing on the oncology questions. Another 6% of the certifying ABIM test is oncology. While we can't cover ALL of oncology in just 10 minutes, here are 10 high yield concepts/facts/vignettes you  should know walking into your IM Boards. 

Today's episode focuses on what you need to know to ace the hematology questions for your 2024 IM boards. 6% of the ABIM exam is hematology which includes erythrocyte, leukocyte and platelet disorders, coagulation disorders, transfusion medicine, and heme malignancies. We discuss some common vignettes & high yield points.

This week's episode will be focusing on infusion reactions - one of the most common calls we get as heme/onc fellows and high yield facts for new fellows as well as boards. We will go over the important details on mechanisms of infusion reaction, class of drugs that most commonly cause infusion reactions, treatment for infusion reactions, and when/how to re-challenge.

This week's episode will be focusing on common topics both for new fellows & residents. We will go over the important details on some clinically important oncologic emergencies including brain metastases, hypercalcemia, cord compression and SVC syndrome. 

This week's episode will discuss updates from ASCO 2024 next with the practice changing ADRIATIC trial presented by Dr. Spigel during the plenary: Durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC). 

In light of the new academic year today, we are so excited for this special episode, hosting Dr Shikha Jain, who is the founder of Women in Medicine & a GI oncologist, & involved with ASCO Women's Networking Center. She shares some of her tips for new doctors, and a few for new attendings.

Today's episode is an update on AML (acute myeloid leukemia). In Part 2 we discuss the treatment options for first-line, as well as relapsed/refractory disease. We are so honored to have Dr. Catherine Lai here with us who is Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at UPenn.

Today's episode is an update on AML (acute myeloid leukemia). In Part 1 we discuss the usual presentation, diagnostic work-up, and updates on the classification of AMLs. We are so honored to have Dr. Catherine Lai here with us who is Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at UPenn.

This week's episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.

Today's episode is updating what you need to know regarding the treatment of metastatic melanoma. We are so honored to have Dr. Michael Atkins here with us today, who is the first author of the practice changing DREAMseq trial, and provides his expertise on this important topic.

Today's episode is a 2024 update on what to know regarding the risk factors, diagnostic work-up, staging and treatment of localized melanoma. We are so honored to have Dr. Michael Atkins here with us today who is deputy director of the Georgetown Lombardi Comprehensive Cancer Center . He is an internationally recognized expert in the management of patients with high-risk and metastatic melanoma or kidney cancer. 

This week's episode will be focusing on the second part of genetic syndromes with risk of malignancy. Last week we covered Li Fraumeni, Lynch, FAP, BRCA ½ and Cowdens. This week we are going to cover the syndromes associated with RCC as well as MEN 1 and 2 and a few others. 

This week's episode will be focusing on genetic syndromes with increased risk of malignancies. In Part 1 we discuss Li-Fraumeni, Lynch Syndrome, FAP, BRCA 1 and 2, and Cowden's syndrome.

Today's episode we will cover 2024 updates for metastatic renal cell carcinoma. We will discuss risk categories, treatment options, and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!